MorphoSys AG appointed Lucinda Crabtree, Ph.D., will join MorphoSys as Chief Financial Officer. She will start in the third quarter 2023 at the latest. Lucinda Crabtree joins MorphoSys from Autolus Therapeutics, a clinical-stage biopharmaceutical company developing T cell therapies, where she most recently served as Chief Financial Officer.

In her previous roles at Autolus she led Finance, Business Strategy and Planning, as well as Investor Relations and Corporate Communications functions. Prior to her time at Autolus, Lucinda worked for several years as a senior investment professional on both the buy and the sell sides, and she served as a board observer for several private healthcare companies. Firms she has worked at include Woodford Investment Management, Panmure Gordon, Goldman Sachs, J.P. Morgan and Jefferies.

Lucinda started her career as a research scientist at a U.K.-based biotech company. She holds a Bachelors of Science degree in Physiology and Pharmacology from University College London and a Ph.D. in Pharmacology from University College London.